Sign in
Taking peopleNo phase

Predicting hemophagocytic lymphohistiocytosis in adults after a donor stem cell transplant

Studies whether routine blood tests can flag hemophagocytic lymphohistiocytosis early in adults after donor transplant.

Key facts

Who runs it
Peking University People's Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
Status
Recruiting
People taking part
10,000 people, planned
Started
19 Oct 2026
Expected to end
31 Dec 2029
Type of study
Observational, 3 groups
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having their first allogeneic hematopoietic stem cell transplant (stem cells from a donor) at a participating center in China. It studies a severe inflammatory complication called HLH after transplant.

Age
18 years or older at the first allogeneic hematopoietic stem cell transplant.
Sex
All sexes can join.
Disease stage
People having their first allogeneic hematopoietic stem cell transplant at a participating center during the study period.
Earlier treatment
People who had an allogeneic hematopoietic stem cell transplant before cannot join.

Main reasons for not taking part

  • Transplant using the person's own cells (autologous), or a transplant that is not a stem cell transplant
  • HLH diagnosed before the transplant, or a transplant done mainly to treat HLH
  • A previous allogeneic hematopoietic stem cell transplant
  • Identity, transplant date or key outcome information cannot be checked
  • Refusing to take part or to allow use of clinical information

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age 18 years or older at first allogeneic hematopoietic stem cell transplantation; First allogeneic hematopoietic stem cell transplantation performed at a participating center within the study period; Verifiable transplantation date and basic clinical information. Written informed consent from the participant or legally authorized representative for prospective participation. Retrospective records are used under the applicable ethics-approved consent or waiver procedures

Who cannot take part

  • Autologous transplantation or transplantation other than hematopoietic stem cell transplantation; HLH diagnosed before transplantation, or transplantation performed primarily for HLH; Previous allogeneic hematopoietic stem cell transplantation. Patient identity, transplantation date, or key outcome information cannot be verified; Explicit refusal to participate or to permit the use of clinical information for this study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation. Its signs can overlap with those of infection and other transplant complications, making early recognition difficult. This study will examine whether changes in routine blood tests and clinical information can help identify patients who may develop HLH during the following seven days.

Read full original descriptionShow less

The study will combine a review of existing medical records with prospective follow-up at participating hospitals in China. Approximately 20,000 adults undergoing their first allogeneic transplantation will be included, with approximately 400 post-transplant HLH cases expected. Historical records will be used to develop the prediction model. Data from independent centers and prospectively enrolled patients will be used to validate the model.

Participants will be followed for one year after transplantation. Those who develop HLH during that year will also be followed for 90 days after HLH onset. The study will describe HLH occurrence, associated factors, treatments, and survival. All tests and treatments will remain part of routine care. No additional research samples or laboratory tests will be required, and model predictions will not be used to guide treatment.

The 3 groups in the trial

  • Retrospective cohort

    Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.

  • Prospective cohort

    Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.

  • Retrospective/Prospective cohort

    Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hemophagocytic Lymphohistiocytosis After Hematopoietic Stem Cell Transplantation: A Multicenter Ambispective Longitudinal Cohort Study
Plain-language title
Predicting hemophagocytic lymphohistiocytosis in adults after a donor stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
29 October 2026